Jun 2026 (Q2 FY26) — Aug 4, 2026
OrthoPediatrics Q2 FY26 — Record Patient Impact and Adjusted EBITDA, Raised Full-Year Revenue Guidance
Read the full callOrthoPediatrics (KIDS) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
OrthoPediatrics earnings: last reported Tue, 4 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 70.5 | +15.4% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -5.8 | +11.7 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -7.2 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$22.03 +0.36% · +$0.08
Performance +27.8% 1Y
1Y: $17.24 on 17 Oct 2025 → $22.03. High $26.5 (19 Aug 2026), low $14.64 (29 Apr 2026).
- Previous close
- $21.95
- 52-week range
- $14.64 – $26.5
- One year
- +25.10%
Overview
- Symbol
- KIDS
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
OrthoPediatrics earnings calls (KIDS)
Financials
What the filings say
Net profit, year on year: −1% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 55 | 53 | 52 | 61 | 61 | 62 | 59 | 71 |
| Operating profit | -6 | -14 | -11 | -11 | -9 | -8 | -8 | -4 |
| Operating margin | −10.2% | −26.7% | −20.9% | −17.4% | −15.4% | −13.3% | −14.0% | −5.8% |
| Other income | -4 | -2 | 1 | 4 | -2 | -2 | -3 | -3 |
| Interest | 0 | 1 | 1 | 1 | 2 | 2 | 2 | 3 |
| Profit before tax | -9 | -16 | -10 | -7 | -12 | -10 | -11 | -7 |
| Tax rate | 13.3% | 2.1% | −1.9% | −0.7% | 1.1% | −3.5% | 1.6% | −3.4% |
| Net profit | -8 | -16 | -11 | -7 | -12 | -10 | -11 | -7 |
| EPS ($ per share) | -0.34 | — | -0.46 | -0.30 | -0.50 | — | -0.45 | -0.30 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -115 | -129 | -162 | -178 | -177 | -198 | -236 | -275 |
| Total liabilities | 30 | 40 | 86 | 79 | 49 | 62 | 119 | 162 |
| Fixed assets | 13 | 21 | 27 | 29 | 34 | 41 | 51 | 50 |
| Investments | — | 0 | 55 | 46 | 109 | 49 | 25 | 41 |
| Total assets | 112 | 182 | 320 | 304 | 428 | 439 | 473 | 509 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -16 | -18 | -19 | -13 | -22 | -27 | -27 | -5 |
| Cash from investing | -6 | -62 | -70 | -7 | -113 | 42 | -13 | -44 |
| Cash from financing | 40 | 91 | 47 | 0 | 136 | 7 | 53 | 24 |
| Net cash flow | 18 | 11 | -42 | -21 | 1 | 23 | 13 | -24 |
| Capital expenditure | -5 | -12 | -11 | -8 | -10 | -17 | -14 | -11 |
| Free cash flow | -21 | -30 | -29 | -21 | -32 | -44 | -41 | -16 |
Insider filings
43 filings between Nov 10, 2025 and Sep 10, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$47.75M
26 sales by 8 insiders
Compensation
not trading decisions- 15
- Award — granted as compensation
Also filed: 2 gifts.
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Squadron Capital LLC | — | $15.58M | Sep 10, 2026 |
| Pritzker Jennifer N. | — | $15.58M | Sep 10, 2026 |
| Pelizzon David R | — | $15.58M | Sep 10, 2026 |
| Bailey David R | — | $337.0K | Mar 16, 2026 |
| Hite Fred | — | $224.1K | Mar 16, 2026 |
| Gerritzen Daniel J | — | $148.6K | Mar 16, 2026 |
| Hauser Joseph W | — | $148.3K | Mar 16, 2026 |
| Odle Gregory A | — | $145.5K | Mar 16, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Sep 10, 2026 | Squadron Capital LLC 10% owner | Sale | 302,369 | $6.35M |
| Sep 10, 2026 | Pritzker Jennifer N. 10% owner | Sale | 302,369 | $6.35M |
| Sep 10, 2026 | Pelizzon David R Director | Sale | 302,369 | $6.35M |
| Sep 2, 2026 | Pritzker Jennifer N. 10% owner | Sale | 22,500 | $525.4K |
| Sep 2, 2026 | Squadron Capital LLC 10% owner | Sale | 22,500 | $525.4K |
| Sep 2, 2026 | Pelizzon David R Director | Sale | 22,500 | $525.4K |
| Sep 1, 2026 | Squadron Capital LLC 10% owner | Sale | 10,131 | $234.0K |
| Sep 1, 2026 | Pritzker Jennifer N. 10% owner | Sale | 10,131 | $234.0K |
| Sep 1, 2026 | Pelizzon David R Director | Sale | 10,131 | $234.0K |
| Aug 28, 2026 | Squadron Capital LLC 10% owner | Sale | 326,700 | $7.53M |
| Aug 28, 2026 | Pelizzon David R Director | Sale | 326,700 | $7.53M |
| Aug 28, 2026 | Pritzker Jennifer N. 10% owner | Sale | 326,700 | $7.53M |
| Aug 26, 2026 | Pelizzon David R Director | Sale | 18,000 | $437.0K |
| Aug 26, 2026 | Squadron Capital LLC 10% owner | Sale | 18,000 | $437.0K |
| Aug 26, 2026 | Pritzker Jennifer N. 10% owner | Sale | 18,000 | $437.0K |
| Aug 25, 2026 | Squadron Capital LLC 10% owner | Sale | 16,300 | $403.3K |
| Aug 25, 2026 | Pritzker Jennifer N. 10% owner | Sale | 16,300 | $403.3K |
| Aug 25, 2026 | Pelizzon David R Director | Sale | 16,300 | $403.3K |
| Aug 24, 2026 | Squadron Capital LLC 10% owner | Sale | 4,000 | $103.0K |
| Aug 24, 2026 | Pritzker Jennifer N. 10% owner | Sale | 4,000 | $103.0K |
| Aug 24, 2026 | Pelizzon David R Director | Sale | 4,000 | $103.0K |
| Jun 9, 2026 | Ruf Harold Director | Award | 11,436 | $0 |
| Jun 9, 2026 | Riccitelli Samuel D Director | Award | 11,436 | $0 |
| Jun 9, 2026 | Fischer Kelly Laine Director | Award | 11,436 | $0 |
| Jun 9, 2026 | Hughes Bryan W Director | Award | 11,436 | $0 |
| Jun 9, 2026 | Pelizzon David R Director | Award | 11,436 | $0 |
| Jun 9, 2026 | Bailey David R President and CEO | Award | 119,140 | $0 |
| Jun 9, 2026 | Infante (Reynolds) Marie C Director | Award | 11,436 | $0 |
| Jun 9, 2026 | Throdahl Mark C Director | Award | 11,436 | $0 |
| Jun 9, 2026 | McDonald Jimmy Duane Director | Award | 11,436 | $0 |
| Jun 9, 2026 | Dyer George Sinclair Mitchell Director | Award | 11,436 | $0 |
| May 13, 2026 | Gerritzen Daniel J General Counsel and Secretary | Gift | 2,479 | $0 |
| Mar 16, 2026 | Bailey David R President and CEO | Sale | 19,535 | $337.0K |
| Mar 16, 2026 | Gerritzen Daniel J General Counsel and Secretary | Sale | 8,614 | $148.6K |
| Mar 16, 2026 | Odle Gregory A President of Scoliosis | Sale | 8,433 | $145.5K |
| Mar 16, 2026 | Hite Fred COO and CFO | Sale | 12,993 | $224.1K |
| Mar 16, 2026 | Hauser Joseph W Pres. Trauma & Def. Correction | Sale | 8,596 | $148.3K |
| Mar 15, 2026 | Gerritzen Daniel J General Counsel and Secretary | Award | 47,380 | $0 |
| Mar 15, 2026 | Hite Fred COO and CFO | Award | 77,405 | $0 |
| Mar 15, 2026 | Hauser Joseph W Pres. Trauma & Def. Correction | Award | 65,700 | $0 |
| Mar 15, 2026 | Odle Gregory A President of Scoliosis | Award | 47,380 | $0 |
| Dec 29, 2025 | Bailey David R President and CEO | Gift | 1,600 | $0 |
| Nov 10, 2025 | Fischer Kelly Laine Director | Award | 4,345 | $0 |
| Aug 21, 2025 | Hite Fred COO and CFO | Purchase | 5,076 | $98.5K |
| May 23, 2025 | Dyer George Sinclair Mitchell Director | Award | 8,401 | $0 |
| May 23, 2025 | McDonald Jimmy Duane Director | Award | 8,401 | $0 |
| May 23, 2025 | Schlotterback Terry D Director | Award | 8,401 | $0 |
| May 23, 2025 | Ruf Harold Director | Award | 8,401 | $0 |
| May 23, 2025 | Infante (Reynolds) Marie C Director | Award | 8,401 | $0 |
| May 23, 2025 | Hughes Bryan W Director | Award | 8,401 | $0 |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for ORTHOPEDIATRICS CORP
Free account. Everything above stays public.
Write why you follow ORTHOPEDIATRICS CORP and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading